Business context and reporting period
Neurocrine Biosciences, Inc. filed this Form 8-K concerning a Chief Medical Officer transition. The report is dated September 25, 2026, and was signed September 28, 2026; the personnel changes took effect September 25 and September 28, respectively. This filing does not report quarterly or annual operating results.
Key financial and compensation information
- No company revenue, profit, cash flow, margin, debt, or liquidity figures are reported.
- Incoming Chief Medical Officer Eiry W. Roberts, M.D., will receive an annual base salary of $825,000 and is eligible for a 2026 target cash incentive bonus equal to 60% of base pay earned during the year.
- Equity awards, subject to continued employment on the grant date, have target values of approximately $625,000 in stock options, $250,000 in restricted stock units, and $375,000 in performance-vesting restricted stock units. The share amounts will be based on the stock price on the grant date.
- Options are scheduled to vest monthly over four years; regular restricted stock units annually over four years; performance-vesting units under the terms of the February 2026 executive awards.
- Former CMO Sanjay Keswani, M.D., is entitled to severance benefits under the company’s Executive Severance Plan, subject to its terms. The filing does not state the amount.
Management changes and material developments
The Board appointed Dr. Roberts to succeed Dr. Keswani, effective September 28, 2026. Dr. Keswani and the Board mutually agreed to end his CMO service on September 25, 2026. The company expects to enter into an amended and restated employment agreement with Dr. Roberts, effective September 28; it anticipates filing the agreement with its Form 10-Q for the quarter ended September 30, 2026.
Dr. Roberts’s equity awards outstanding before the appointment will remain outstanding and continue to vest under their existing terms. The new equity awards are to be granted automatically two business days after filing the company’s first Form 10-Q following the transition date, provided she remains employed then.
Outlook, risks, and unusual items
The filing’s forward-looking statements include anticipated severance benefits, execution of the employment agreement, compensation and future filing of that agreement. These statements depend on assumptions and may differ from actual outcomes. The company cites risks relating to the future plans of the company and the individuals, its business generally, and risks described in its other SEC filings. It undertakes no obligation to update forward-looking statements except as required by law.
Important facts for investors to verify
- Review the final employment agreement when filed, including its full terms and any differences from this summary.
- Confirm the timing and actual share amounts of Dr. Roberts’s equity grants, which depend on the grant-date stock price and her continued employment.
- Review the Executive Severance Plan and subsequent disclosures for the actual benefits payable to Dr. Keswani.
- Check subsequent filings for updates to the transition, compensation arrangements, or related risks.